Building the clinical evidence platform
Founded in Switzerland in 2016. The platform was built from 2023 and has been on the market since January 2026.

Our story
Vitruvian Shield SA was founded in Switzerland in 2016. Its first years went into clinical work in epilepsy, close to patients and clinicians, before the current platform was designed and built from 2023 and brought to market in January 2026.
That order matters. The platform was shaped by what clinical teams need to show, not adapted to it afterwards: wearable and connected-device data and patient-reported outcomes in one traceable dataset, next to the EDC the sponsor already uses.
Today, Vitruvian Shield provides post-market clinical evidence and regulatory documents for medical device manufacturers, and hybrid trial platform components for CROs and sponsors. The evidence layer comes first: data with provenance, identity assurance, a signal-confidence score and an audit trail, designed to support ALCOA++ data-integrity principles, GDPR requirements, ICH E6(R3) and FDA 21 CFR Part 11. Studies are in preparation with Portuguese university hospitals and test beds.
Clinical groundwork
Founded in Switzerland in 2016. Years of clinical work in epilepsy, with a first test in a Swiss university hospital in 2020.
Build
The platform you see today was designed and built from 2023, with teams in Switzerland, Portugal and Armenia.
Group
Vitruvian Shield Holding SA created at Biopôle, Epalinges, as parent of the group.
In market
Product completed in December 2025. Available to sponsors, CROs, device makers and hospitals since January 2026.
Non-dilutive capital and recognition
Awards and selections received by Vitruvian Shield and by its founder, Paulo Martins.
European CEO of the Year 2024-2025
Awarded to Paulo Martins for leadership in AI-driven decentralized clinical trial infrastructure.
Portuguese National Innovation Award 2024
Awarded to Paulo Martins for his contribution to the national innovation ecosystem.
APDC Health Award, First Place 2025
Awarded by the Portuguese Association for the Development of Communications.
World Summit Awards Portugal 2024 Winner
In the Health and Well-Being category.
Finalist, Global Leverage Award 2026
Finalist, one of five; final held at EPFL, organised by Corporate Connections Switzerland.
Frontiers Health 2026, Berlin
Pitched in the Start-up and Scale-up Discovery session, 20–21 October 2026.
Non-dilutive research and innovation funding secured to date.
Innosuisse · Aide Suisse à la Montagne
Research grants
Innosuisse (Switzerland), Aide Suisse à la Montagne (Switzerland). Non-dilutive research and innovation funding secured to date.
Additional financing disclosures are shared privately with qualified investors on request.
Group entities
Vitruvian Shield operates through legal entities across Europe, the South Caucasus, and the Middle East.
- EpalingesHeadquarters · Vitruvian Shield Holding SA & Vitruvian Shield SA
- AveiroPortuguese subsidiary · Vitruvian Shield PT LDA
- YerevanEngineering centre · Vitruvian Shield AM
- DubaiUAE market entry · Vitruvian Shield FZCO (DMCC)
Global presence
Headquartered in Switzerland. Operating across Europe, the South Caucasus, and the Middle East.
Switzerland
Vitruvian Shield Holding SA (CHE-380.090.655) and Vitruvian Shield SA (CHE-390.132.812). Headquartered at Biopole Life Sciences Campus, Rue de la Corniche 3a, 1066 Epalinges. Platform architecture, regulatory strategy, and business development.
Portugal
Vitruvian Shield PT LDA (NIPC 517508729). Based at PCI Creative Science Park Aveiro Region, Ílhavo. Clinical operations, software development, and clinical trial execution.
Armenia
Vitruvian Shield AM (Reg. 264.110.1489516). Operating from Hakob Hakobyan 3, Mergelyan Institute, Yerevan. Engineering hub for AI/ML, data engineering, and platform infrastructure.
UAE
Vitruvian Shield FZCO (Licence DMCC-945790). Registered at DMCC, Dubai. Market expansion and partnerships with Gulf healthcare systems.
Studies and partner work
Studies in preparation and partner work on the Vitruvian Shield platform. No study result is claimed.
Oncology electronic survey study, ULS Coimbra
In preparation. An observational oncology eSurvey study with clinical investigators at ULS Coimbra, prepared through the TEF-Health facility operated by Instituto Pedro Nunes, using EORTC QLQ-C30 and PRO-CTCAE.
PT-EPI-DCT-002, decentralised seizure monitoring in adult epilepsy, ULS Santa Maria
In preparation. A single-site decentralised study protocol, version 2.0, prepared with ULS Santa Maria in Lisbon under the TB4Health non-binding letter of intent of 28 June 2026; ethics submission targeted before the end of 2026.
Leadership
The named executives accountable for platform direction, regulatory posture, engineering and quality across our five legal entities in four countries.
Full team, including engineering, clinical, and strategic advisors, listed below.
Our people
Teams and entities in Switzerland, Portugal, Armenia and the UAE. Selected members shown below.
Executive leadership

Paulo Martins
Founder, President & CEO
Clinical and strategic advisors
Team
Show team membersHide team members
Our values
The principles that guide every decision we make.
Regulatory integrity
Compliance isn't a feature, it's the foundation. Every line of code is written with regulatory inspection readiness as a first-class requirement, not an afterthought.
Patient centricity
Technology should reduce patient burden, not add to it. We design every workflow around the question: does this make the patient's experience better?
Scientific rigour
Clinical decisions must be grounded in validated data. We build tools that generate evidence you can trust, no shortcuts, no compromises on data integrity.
Speed of execution
The urgency of clinical research demands velocity. We move fast, ship continuously, and iterate relentlessly, without ever sacrificing quality or compliance.
Work with us, or join us
Talk to us about a study, or contact us about working with the team.














